NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2005

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2016

Conditions

Gastrointestinal Carcinoid TumorIslet Cell TumorLung CancerNeoplastic SyndromeNeuroendocrine Tumor

Interventions

BIOLOGICAL

bevacizumab

5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.

DRUG

5-fluorouracil

2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.

DRUG

leucovorin

200mg/m2 IV q2 wk on day 1 over a 2-hour period.

DRUG

oxaliplatin

200mg/m2 IV q 2 wk on day 1 over a 2-hour period

Trial Locations (2)

94115

Univeristy of California, San Francisco, San Francisco

94589

Kaiser Permanente Medical Center - Vallejo, Vallejo